Bispecific antibody therapies
- 8 December 2023
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2023 (1) , 216-222
Abstract
Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles. The hematological toxicities are common and potentially harmful, and the side effects have hitherto not been reviewed. With many BsAbs recently approved and entering routine clinical use, we have reviewed the rather limited published data and propose recommendations on the management of these toxicities. Our review of the available data confirms that hematological toxicities are among the most common toxicities, with potentially harmful consequences for the patients. Fortunately, hemophagocytic lymphohystiocytosis and disseminated intravascular coagulation are rare. Severe neutropenia and hypogammaglobulinemia are manageable, and their timely treatment and prevention may reduce morbidity and mortality.Keywords
This publication has 45 references indexed in Scilit:
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- FDA approves first bispecificNature Reviews Drug Discovery, 2014
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Rituximab-Associated NeutropeniaSeminars in Hematology, 2010
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006